| Literature DB >> 22877630 |
Kevin R Shreder1, Emme C K Lin, Jiangyue Wu, Julia Cajica, Christopher M Amantea, Yi Hu, Eric Okerberg, Heidi E Brown, Lan M Pham, De Michael Chung, Allister S Fraser, Ethel McGee, Jonathan S Rosenblum, John W Kozarich.
Abstract
KIAA1363 is a serine hydrolase whose activity has been shown to be positively associated with tumor cell invasiveness. Thus, inhibitors of KIAA1363 represent a novel targeted therapy approach towards cancer. AX11890 ((1-bromo-2-naphthyl) N,N-dimethylcarbamate) was identified as a KIAA1363 inhibitor with an IC(50) value of 1.2 μM and was shown using ESI-MS to carbamylate the catalytic residue Ser(191). SAR studies explored both substitution of the 1-bromo group and derivatization of the 6-position. Activity-based protein profiling demonstrated AX13057 inhibited tumor-localized KIAA1363 in SK-OV-3 xenograft-bearing mice.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22877630 DOI: 10.1016/j.bmcl.2012.05.102
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823